MCID: SCH011
MIFTS: 32

Schizotypal Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Schizotypal Personality Disorder

About this section

Aliases & Descriptions for Schizotypal Personality Disorder:

Name: Schizotypal Personality Disorder 10 47 12 36 65
 
Schizotypal Personality 47

Classifications:



External Ids:

Disease Ontology10 DOID:10646
ICD1027 F21
ICD9CM29 301.22
SNOMED-CT59 231486008, 31027006
MeSH36 D012569
NCIt42 C92632
UMLS65 C0036363

Summaries for Schizotypal Personality Disorder

About this section
Disease Ontology:10 A personality disorder that involves a need for social isolation, anxiety in social situations, odd behavior and thinking, and often unconventional beliefs.

MalaCards based summary: Schizotypal Personality Disorder, also known as schizotypal personality, is related to leukemia and hiv-1. An important gene associated with Schizotypal Personality Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways are Immune response Function of MEF2 in T lymphocytes and Metabolism. Affiliated tissues include lung, bone and breast, and related mouse phenotypes are embryo and endocrine/exocrine gland.

Wikipedia:68 Schizotypal personality disorder (STPD) or schizotypal disorder is a mental disorder characterized by... more...

Related Diseases for Schizotypal Personality Disorder

About this section

Graphical network of the top 20 diseases related to Schizotypal Personality Disorder:



Diseases related to schizotypal personality disorder

Symptoms for Schizotypal Personality Disorder

About this section

Drugs & Therapeutics for Schizotypal Personality Disorder

About this section

Drugs for Schizotypal Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Guanfacineapproved, investigationalPhase 4, Phase 25329110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
Guanfacine (INN)
Guanfacine Hydrochloride
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
2Neurotransmitter AgentsPhase 4, Phase 1, Phase 214795
3Adrenergic AgentsPhase 4, Phase 24204
4Adrenergic alpha-2 Receptor AgonistsPhase 4, Phase 2790
5Adrenergic AgonistsPhase 4, Phase 22331
6Adrenergic alpha-AgonistsPhase 4, Phase 21300
7Antihypertensive AgentsPhase 4, Phase 23618
8
DopamineapprovedPhase 1, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
9
Risperidoneapproved, investigationalPhase 1, Phase 2477106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
 
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperdal M-tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone M-tab
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
10
SerotoninPhase 1, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
11Tranquilizing AgentsPhase 1, Phase 23597
12Serotonin AntagonistsPhase 1, Phase 21175
13Serotonin AgentsPhase 1, Phase 22668
14Psychotropic DrugsPhase 1, Phase 25501
15Antipsychotic AgentsPhase 1, Phase 22130
16Central Nervous System DepressantsPhase 1, Phase 210016
17Dopamine AgentsPhase 1, Phase 23084
18Dopamine AntagonistsPhase 1, Phase 2927
19Dopamine AgonistsPhase 2544
20DihydrexidinePhase 24
21
OxytocinapprovedPhase 136650-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
 
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
SID29217903
SID50111741
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
22
Sertralineapproved28279617-96-268617
Synonyms:
(+)-Sertraline
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
(1S,4S)-Sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
79559-97-0 (Hydrochloride)
79617-96-2
AB00514002
AB1004870
AC-15639
AC1L2A41
AC1Q3O5N
AC1Q3XJU
Apo-Sertraline
BIDD:GT0768
BIDD:PXR0193
BPBio1_001285
BRD-K82036761-003-02-1
BRN 5753709
BSPBio_001167
BSPBio_002698
C07246
C17H17Cl2N
CHEBI:9123
CHEMBL809
CID68617
CP 51974
Cp 51974
D02360
DB01104
DB08567
FT-0081122
HSDB 7037
KBio3_001918
 
KBioGR_001724
LS-94179
Lustral
MLS001195647
MLS002222308
MolPort-002-885-860
NCGC00092386-03
NCGC00092386-04
NCGC00092386-05
NCGC00092386-06
NCGC00092386-07
NCGC00092386-08
NCGC00092386-09
Prestwick3_001014
SMR000596516
SPBio_000385
SRE
Sertralina
Sertralina [Spanish]
Sertraline
Sertraline (INN)
Sertraline Hydrochloride
Sertraline [INN:BAN]
Sertraline [Zoloft]
Sertraline hydrochloride
Sertralinum
Sertralinum [Latin]
Spectrum2_000493
Spectrum3_001079
Spectrum4_001232
Sultamicillin Tosylate
UNII-QUC7NX6WMB
Zoloft
cis-(+)-Sertraline
sertraline
sertraline (Zoloft)
23
Aripiprazoleapproved, investigational342129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify DISCMELT
Abilify Discmelt
Abilify Maintena
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
 
CPD000466383
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
24Neurotransmitter Uptake Inhibitors2857
25Antidepressive Agents2367
26Serotonin Uptake Inhibitors1369

Interventional clinical trials:

(show all 17)
idNameStatusNCT IDPhase
1Pharmacology of Cognition in Schizotypal Personality DisorderRecruitingNCT00353379Phase 4
2Schizotypal Personality Disorder RisperidoneCompletedNCT02535156Phase 1, Phase 2
3Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality DisorderRecruitingNCT01466205Phase 2
4A D1 Agonist For Working MemoryRecruitingNCT02507206Phase 2
5CRT-Guanfacine for SPDRecruitingNCT02524899Phase 2
6Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsRecruitingNCT02149823Phase 1
7A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological DysfunctionsCompletedNCT00155519
8Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) StudyCompletedNCT01269710
9Psychosis: Early Detection, Intervention and PreventionCompletedNCT01597141
10Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative SymptomsCompletedNCT00169988
11Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of PsychosisCompletedNCT01619319
12Pergolide for Cognitive Symptoms in Schizotypal Personality DisorderRecruitingNCT00252044
13Risperidone in the Treatment of Psychotic-Like and Deficit Symptoms of Schizotypal Personality DisorderActive, not recruitingNCT00158028
14Extended Specialized Assertive Intervention for First Episode PsychosisActive, not recruitingNCT00914238
15Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode PsychosisActive, not recruitingNCT00157313
16Health Promotion on Young Adults With High Risk Disability for Mental HealthActive, not recruitingNCT01740167
17Aripiprazole Treatment of the ProdromeTerminatedNCT00169949

Search NIH Clinical Center for Schizotypal Personality Disorder


Cochrane evidence based reviews: schizotypal personality disorder

Genetic Tests for Schizotypal Personality Disorder

About this section

Anatomical Context for Schizotypal Personality Disorder

About this section

MalaCards organs/tissues related to Schizotypal Personality Disorder:

33
Lung, Bone, Breast, Testes, Liver, Brain, Bone marrow

Animal Models for Schizotypal Personality Disorder or affiliated genes

About this section

MGI Mouse Phenotypes related to Schizotypal Personality Disorder:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053808.7CACNA1C, COMT, EP300, PSAT1
2MP:00053798.6CACNA1C, COMT, EP300, LBR
3MP:00036318.1CACNA1C, COMT, EP300, LBR, PSAT1

Publications for Schizotypal Personality Disorder

About this section

Articles related to Schizotypal Personality Disorder:

(show top 50)    (show all 181)
idTitleAuthorsYear
1
FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease. (26089602)
2015
2
Germline variant FGFR4 a88p.G388R exposes a membrane-proximal STAT3 binding site. (26675719)
2015
3
Comparison of Optical Coherence Tomography Findings in Patients With Primary Open-angle Glaucoma and Parkinson Disease. (25719240)
2015
4
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis. (26209639)
2015
5
Failed needle decompression of bilateral spontaneous tension pneumothorax. (25900313)
2015
6
K14-EGFP-miR-31 transgenic mice have high susceptibility to chemical-induced squamous cell tumorigenesis that is associating with Ku80 repression. (25082302)
2015
7
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. (25395428)
2014
8
Multidrug resistant tuberculosis versus non-tuberculous mycobacterial infections: a CT-scan challenge. (23453416)
2013
9
Early goal-directed fluid therapy with fresh frozen plasma reduces severe acute pancreatitis mortality in the intensive care unit. (23673124)
2013
10
HSPB1 facilitates the formation of non-centrosomal microtubules. (23826100)
2013
11
HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. (24349422)
2013
12
Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. (23073328)
2012
13
Evaluation of pulmonary disease using static lung volumes in primary ciliary dyskinesia. (22771515)
2012
14
Hmgb3 is regulated by microRNA-206 during muscle regeneration. (22912879)
2012
15
Schizoid Personality Disorder. (22928849)
2012
16
B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. (22661084)
2012
17
Immune modulation in primary vaccinia virus zoonotic human infections. (22229039)
2012
18
The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. (21773992)
2011
19
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. (18689872)
2008
20
Iris root abscess and necrotizing sclerokeratitis caused by Mycobacterium abscessus and presenting as hemorrhagic anterior uveitis. (18216592)
2008
21
Differential expression and activity of matrix metalloproteinase-2 and -9 in the calreticulin deficient cells. (17412577)
2007
22
Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. (17712863)
2007
23
Type V collagen regulates the expression of apoptotic and stress response genes by breast cancer cells. (15389593)
2005
24
Differentiating the pathologies of cerebral malaria by postmortem parasite counts. (14745442)
2004
25
Time course of thoracic epidural pressure and saphenous venous pressure changes with oxytocics after fetus delivery in parturients undergoing cesarean section]. (15552946)
2004
26
Assessing experimental models in myocardial injury: lack of activation of the proteases TACE and calpain in brief ischaemia and reperfusion. (16352107)
2003
27
Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. (14632594)
2003
28
Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. (11809901)
2002
29
Molecular adsorbent recirculating system: albumin dialysis-based extracorporeal liver assist device. (12472950)
2002
30
A novel serine-rich motif in the intercellular adhesion molecule 3 is critical for its ezrin/radixin/moesin-directed subcellular targeting. (11784723)
2002
31
Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction. (11502878)
2001
32
Cloning, characterization, and physical mapping of the canine Prop-1 gene (PROP1): exclusion as a candidate for combined pituitary hormone deficiency in German shepherd dogs. (10773688)
2000
33
Identification of differentially expressed genes during a wool follicle growth cycle induced by prolactin. (10594723)
1999
34
Efficient recruitment of TFIIB and CBP-RNA polymerase II holoenzyme by an interferon-beta enhanceosome in vitro. (9770462)
1998
35
Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. (9065442)
1997
36
A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. (8577704)
1996
37
P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. (9118874)
1996
38
Aniridia-associated cytogenetic rearrangements suggest that a position effect may cause the mutant phenotype. (7795596)
1995
39
Evidence for exclusion of a mutation in NRAMP as the cause of familial disseminated atypical mycobacterial infection in a Maltese kindred. (8592339)
1995
40
Elevated serum levels of transforming growth factor-alpha in breast cancer patients. (8019973)
1994
41
Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. (9205463)
1994
42
Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. (1348017)
1992
43
The effect of antihypertensive therapy on the course of renal failure. (1283193)
1992
44
Morphine and cocaine exert common chronic actions on tyrosine hydroxylase in dopaminergic brain reward regions. (1675665)
1991
45
Pseudoepitheliomatous, keratotic, and micaceous balanitis. (7259225)
1981
46
Infant botulism: new guise for an old disease. (83280)
1978
47
Basilar-vertebral artery insufficiency as a cause of vertigo. (4220283)
1973
48
The diagnosis of endomyocardial fibrosis. (5086889)
1972
49
Congenital pulmonary lymphangiectasis. (5724880)
1968
50
Report on a case of macular degeneration of familial type, Tay's choroiditis, with central choroidal atrophy as a late development. (13155496)
1954

Variations for Schizotypal Personality Disorder

About this section

Expression for genes affiliated with Schizotypal Personality Disorder

About this section
Search GEO for disease gene expression data for Schizotypal Personality Disorder.

Pathways for genes affiliated with Schizotypal Personality Disorder

About this section

Pathways related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.1CACNA1C, EP300
2
Show member pathways
7.1CACNA1C, COMT, EP300, LBR, PSAT1, SULT4A1

GO Terms for genes affiliated with Schizotypal Personality Disorder

About this section

Biological processes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1small molecule metabolic processGO:00442817.9CACNA1C, COMT, LBR, PSAT1, SULT4A1

Sources for Schizotypal Personality Disorder

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet